Gene Therapy in Ophthalmology Competitive landscape

DelveInsight’s, “Gene Therapy in Ophthalmology Competitive landscape, 2026,” report provides comprehensive insights about 80+ companies and 85+ drugs in Gene Therapy in Ophthalmology  Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

• Global coverage

Gene Therapy in Ophthalmology Understanding

Gene Therapy in Ophthalmology Overview

Gene Therapy in Ophthalmology is an emerging and transformative approach aimed at treating a wide spectrum of ocular diseases by addressing their underlying genetic causes. It involves the delivery of therapeutic genetic material into ocular cells to restore, replace, or regulate defective genes, thereby enabling long-term or potentially permanent treatment effects. The eye is particularly well suited for gene therapy due to its small size, compartmentalized structure, accessibility for localized delivery, and relative immune privilege, which reduces systemic exposure and immune-related complications.

Gene delivery can be performed through in vivo methods, where vectors are directly introduced into ocular tissues, or ex vivo approaches, where cells are modified outside the body and then transplanted back. Viral vectors, especially adeno-associated viruses (AAV), are commonly used due to their high efficiency and ability to target specific cell types, although non-viral systems are also under investigation to improve safety and scalability.

Different administration routes such as subretinal, intravitreal, and suprachoroidal injections allow targeted delivery depending on the affected part of the eye. Gene therapy has shown significant promise in inherited retinal diseases, which are often caused by single-gene mutations and are therefore ideal candidates for gene replacement or gene editing strategies. In addition, ongoing research is exploring its application in more common and complex conditions, including glaucoma, age-related macular degeneration, diabetic retinopathy, and corneal disorders, where it may provide sustained therapeutic benefits and reduce treatment burden. Advances in genome editing technologies, such as CRISPR-based systems, are further expanding the potential of gene therapy by enabling precise correction of genetic defects.

Therapeutic applications of gene therapy in ophthalmology span a broad range of ocular disorders, with the most advanced progress seen in inherited retinal diseases. These conditions, often caused by single-gene mutations, are well suited for gene replacement strategies that introduce functional copies of defective genes to restore visual function or slow degeneration. Beyond gene replacement, approaches such as gene silencing and gene editing are being used to suppress harmful mutations or directly correct genetic defects at the DNA level. Gene therapy is also being explored for complex, multifactorial diseases such as age-related macular degeneration and diabetic retinopathy, where it can deliver genes encoding anti-angiogenic or anti-inflammatory factors to provide sustained therapeutic effects and reduce the need for repeated intravitreal injections.

In glaucoma, gene therapy strategies aim to lower intraocular pressure by modifying aqueous humor outflow pathways or to provide neuroprotection to retinal ganglion cells, thereby preventing vision loss. For corneal diseases, gene therapy offers potential in treating inherited dystrophies, promoting wound healing, and reducing fibrosis or inflammation. Additionally, applications extend to optic nerve disorders and uveitis, where targeted gene delivery can modulate immune responses or support neuronal survival. Emerging approaches also include optogenetics, which introduces light-sensitive proteins into retinal cells to restore vision in advanced degenerative conditions, and cell-based gene therapies that combine genetic modification with regenerative strategies.

Discover the latest Gene Therapy in Ophthalmology pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Gene Therapy in Ophthalmology Pipeline Report Highlights

• In March 2026, Ocugen, Inc. announced that enrollment is now complete for the OCU400 Phase III liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial, topline data will be available in the first quarter of 2027. These data are anticipated to support the Biologics License Application (BLA) filing for OCU400 and potential approval in 2027.
• In March 2026, Complement Therapeutics GmbH (CTx) announced that the first patient has been dosed in Opti-GAIN, the Company’s first-in-human Phase I/II clinical trial of CTx001 in patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
• In February 2026, SparingVision announced that it has successfully completed dosing in its Phase I/II PRODYGY clinical trial evaluating the company’s novel gene-agnostic therapy SPVN06 for the treatment of retinitis pigmentosa.
• In February 2026, 4D Molecular Therapeutics a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, announced enrollment completion for 4FRONT-1, the first Phase III clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
• In February 2026, Opus Genetics, Inc. announced new clinical data from its ongoing Phase I/II study of OPGx-BEST1 gene therapy, presented at the 49th Annual Meeting of the Macula Society, in San Diego, California.
• In January 2026, SpliceBio, a clinical-stage genetic medicines company pioneering protein splicing to address diseases caused by mutations in large genes, announced that the first patient has been dosed in the Part B dose-expansion portion of the Phase I/II ASTRA clinical trial of SB-007, a dual adeno-associated viral (AAV) vector gene therapy for the treatment of Stargardt disease.
• In November 2025, Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase I/II clinical trial for Best disease (BEST1).
• In October 2025, Eli Lilly and Company and Adverum Biotechnologies, Inc. announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc. including its lead product candidate, Ixo-vec.

Gene Therapy in Ophthalmology Company and Product Profiles (Marketed Therapies)

1. Company Overview: Roche

Roche is a global, research-driven healthcare company headquartered in Basel, Switzerland, with a history spanning more than 125 years. It has evolved into one of the world’s largest biotechnology companies and a leading provider of in vitro diagnostics, delivering innovative solutions across major disease areas. The company operates through two core divisions pharmaceuticals and diagnostics which together enable a comprehensive approach to healthcare, ranging from disease prevention and diagnosis to treatment and monitoring. Roche focuses on advancing science to develop transformative medicines and diagnostic tools that improve patient outcomes and support personalized healthcare. With a strong commitment to long-term innovation, sustainability, and collaboration with partners, governments, and healthcare stakeholders, the company aims to address diseases with high societal burden and contribute to a healthier future globally.

Product Description: Luxturna

Luxturna (voretigene neparvovec-rzyl) is the first FDA-approved, one-time gene therapy for inherited retinal diseases caused by confirmed RPE65 gene mutations, which lead to vision loss. It works by delivering a functional gene to retinal cells to restore the visual cycle. It is administered via a single subretinal injection in each eye to patients with sufficient remaining viable retinal cells. The therapy is specifically indicated for individuals who have confirmed biallelic RPE65 mutations and sufficient viable retinal cells, as these conditions are necessary for the treatment to be effective. It is administered as a surgical, subretinal injection in each eye, typically performed separately over a short interval. Unlike conventional treatments that require repeated dosing, Luxturna is designed as a single-administration therapy, offering long-term therapeutic benefit by addressing the underlying genetic cause of the disease.

2. Company Overview: Neurotech Pharmaceuticals, Inc

Neurotech Pharmaceuticals, Inc. is a private biotechnology company focused on developing transformative therapies for chronic eye diseases, particularly retinal disorders. The company utilizes its proprietary Encapsulated Cell Therapy (ECT) platform, a novel drug delivery technology designed to provide sustained release of therapeutic proteins to the eye for the treatment of chronic retinal diseases such as Macular Telangiectasia Type 2 (MacTel). Through ongoing clinical research and innovation, Neurotech aims to develop long-term treatment solutions that improve visual outcomes and reduce treatment burden for patients and physicians.

Product Description: ENCELTO

ENCELTO is the first FDA-approved encapsulated cell-based gene therapy developed by Neurotech Pharmaceuticals, Inc. for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). The therapy utilizes the company’s proprietary Encapsulated Cell Therapy (ECT) platform, in which genetically modified retinal pigment epithelial cells are enclosed within a semipermeable capsule implanted into the eye to continuously release recombinant human ciliary neurotrophic factor (rhCNTF), a neuroprotective protein that supports photoreceptor survival. ENCELTO is designed to provide long-term intraocular protein delivery and has demonstrated the ability to slow photoreceptor degeneration in Phase 3 clinical studies. The therapy received FDA approval in March 2025 and represents a novel sustained-delivery approach for chronic retinal diseases.

Gene Therapy in Ophthalmology Company and Product Profiles (Pipeline Therapies)

1. Company Overview: REGENXBIO Inc.

REGENXBIO is a clinical-stage biotechnology company focused on advancing the curative potential of gene therapy to treat a wide range of diseases. The company develops gene therapy candidates designed to deliver functional genes into cells, either to correct underlying genetic defects or to enable sustained production of therapeutic proteins, with the goal of providing long-lasting effects from a single administration. Its research and development efforts are primarily centered on rare and retinal diseases, as well as metabolic and neurodegenerative conditions. A key differentiator of REGENXBIO is its proprietary NAV® Technology Platform, which utilizes adeno-associated virus (AAV) vectors for efficient and targeted gene delivery, and is also licensed to other biotechnology and pharmaceutical companies to support broader innovation in the field.

Product Description: ABBV-RGX-314

ABBV-RGX-314 is an investigational one-time gene therapy designed to treat wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR) by providing sustained anti-VEGF treatment. It uses an AAV8 vector to deliver a gene that enables eye cells to produce an anti-VEGF protein, aiming to eliminate the need for frequent, recurring, lifelong eye injections. AbbVie and REGENXBIO are advancing the development of two separate routes of administration of ABBV-RGX-314 to the eye, through a standardized subretinal delivery procedure as well as delivery to the suprachoroidal space. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments to the suprachoroidal space of the eye. The drug is currently in Phase III stage of development for the treatment of patients with neovascular age-related macular degeneration (wet AMD).

2. Company Overview: PharmaMar

PharmaMar is a global biopharmaceutical company headquartered in Madrid, Spain, focused on the discovery, development, and commercialization of innovative therapies, particularly in oncology. The company is distinguished by its unique approach of deriving bioactive compounds from marine sources, which serve as the foundation for its anticancer drug discovery efforts. With a strong emphasis on research and development, PharmaMar has built a robust pipeline of novel therapeutics targeting various solid and hematological malignancies, alongside marketed products such as Yondelis®. In addition to its oncology focus, PharmaMar operates through specialized subsidiaries that expand its capabilities across related areas of biotechnology.

Product Description: Tivanisiran

Tivanisiran (SYL1001) is an investigational small interfering RNA (siRNA) eye drop designed by Sylentis to treat Dry Eye Disease (DED) by reducing ocular pain and inflammation. It works by silencing the TRPV1 gene, which is involved in detecting pain and triggering inflammatory responses on the ocular surface. It is a preservative-free eye drop, reducing irritation often caused by traditional eye drop preservatives. It acts in the detection, transmission and regulation of sensation of pain in the eye, as well as in the mediation of innate inflammatory response, mechanism whose regulation is key for the treatment and prevention of this disease. The drug has recently completed Phase III clinical trial for the treatment of patients with dry eyes.

3. Company Overview: Johnson & Johnson

Johnson & Johnson is a global healthcare leader with a history spanning more than 140 years, dedicated to advancing human health through innovation across the full spectrum of medical care. Headquartered in the United States, the company operates through two primary business segments Innovative Medicine and MedTech focusing on developing pharmaceuticals and medical technologies that address some of the world’s most complex diseases. Its pharmaceutical portfolio spans key therapeutic areas such as oncology, immunology, neuroscience, and cardiopulmonary diseases, while its MedTech division delivers advanced solutions in fields including surgery, orthopaedics, cardiovascular care, and vision. Guided by its longstanding values and commitment to addressing unmet medical needs, Johnson & Johnson aims to deliver transformative, more precise, and less invasive healthcare solutions that help people live longer and healthier lives.

Product Description: JNJ-81201887

JNJ-81201887 (JNJ-1887) is an investigational, one-time (AAV-based gene therapy) designed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD) by delivering a soluble form of CD59 (sCD59) to protect retinal cells from complement-mediated damage. Early-phase trials have shown it to be well-tolerated with a manageable safety profile, demonstrating potential to reduce GA lesion growth over 24 months. It is a recombinant adeno-associated virus serotype 2 (AAV2) vector that carries genetic instructions for retinal cells to produce a soluble form of CD59 (AAVCAGsCD59). This protein inhibits the formation of the Membrane Attack Complex (MAC), which is believed to be a key driver in the destruction of retinal pigment epithelium (RPE) cells in AMD. The drug is currently in Phase II stage of development for the treatment of patients with dry age-related macular degeneration.

4. Company Overview: Frontera Therapeutics, Inc.

Frontera Therapeutics is a global, clinical-stage biotechnology company dedicated to developing innovative, high-quality, and affordable gene therapies based on recombinant adeno-associated virus (rAAV) technology. The company focuses on addressing significant unmet medical needs across multiple therapeutic areas, particularly in ophthalmology, as well as cardiology and neurology. With an international presence, Frontera has established research, clinical development, and manufacturing operations in the United States and China, supported by a world-class team of scientists and collaborations with leading academic and industry experts.

Product Description: FT-001

FT-001 is a lead gene therapy candidate developed by Frontera Therapeutics for the treatment of inherited retinal diseases, particularly those caused by mutations in the RPE65 gene such as Leber congenital amaurosis type 2 (LCA-2). The therapy utilizes a recombinant adeno-associated virus (AAV) vector to deliver a functional copy of the human RPE65 gene directly into retinal cells through a one-time subretinal injection, enabling restoration of the visual cycle and improvement in visual function. The drug is currently in Phase II stage of development for the treatment of patients with biallelic RPE65 mutation-associated retinal dystrophy.

5. Company Overview: Ray Therapeutics

Ray Therapeutics is a clinical-stage biotechnology company focused on developing innovative vision restoration therapies for patients with degenerative retinal diseases. Founded in 2021, the company is pioneering the use of optogenetics a technology that enables the reprogramming of retinal cells to respond to light to restore visual function in individuals who have lost vision, regardless of the underlying genetic cause. Its therapeutic approach involves engineering light-sensitive proteins into surviving retinal neurons, allowing them to transmit visual signals to the brain and potentially reverse blindness. The company is advancing a pipeline of optogenetic gene therapies targeting conditions such as retinitis pigmentosa, Stargardt disease, and geographic atrophy, with programs spanning preclinical and clinical development.

Product Description: RTX-015

RTx-015 is an investigational, optogenetic gene therapy developed by Ray Therapeutics to restore vision in patients with advanced retinal degenerative diseases, such as retinitis pigmentosa (RP) and choroideremia. It uses a single intravitreal injection to deliver light-sensitive proteins to retinal cells, bypassing damaged photoreceptors to restore sight regardless of the underlying genetic mutation. Unlike traditional gene replacement therapies, RTx-015 introduces a gene that encodes a bioengineered, highly light-sensitive protein into surviving retinal cells (such as bipolar or ganglion cells). This makes these cells responsive to light, enabling them to take over the function of lost photoreceptors and send visual signals to the brain. The drug is currently in Phase I stage of development for the treatment of patients with retinitis pigmentosa or choroideremia.

6. Company Overview: MeiraGTx

MeiraGTx is a vertically integrated, clinical-stage biotechnology company focused on the development of genetic medicines to treat both inherited and more common diseases. Founded in 2015 and headquartered in New York and London, the company is dedicated to advancing gene therapy approaches that deliver targeted, long-lasting therapeutic effects through localized administration. Its pipeline spans multiple therapeutic areas, including ophthalmology (particularly inherited retinal diseases), neurodegenerative disorders such as Parkinson’s disease, and conditions like radiation-induced xerostomia. A key strength of MeiraGTx lies in its comprehensive, end-to-end capabilities, including in-house manufacturing infrastructure with GMP-certified viral vector production and quality control facilities.

Product Description: AAV-VEGFR2

AAV-VEGFR2 is an investigational adeno-associated virus (AAV) gene therapy designed to treat wet age-related macular degeneration (wet AMD) and other vascular diseases by targeting the VEGFR2 receptor. Developed by MeiraGTx, this approach aims to inhibit pathological angiogenesis (new, leaky blood vessel growth) by expressing a therapeutic protein that blocks the VEGF/VEGFR2 signaling pathway, providing a potentially long-lasting alternative to recurring anti-VEGF injections. The drug is currently in preclinical stage of development for the treatment of patients with retinitis pigmentosa or choroideremia.

Further product details are provided in the report……..

Gene Therapy in Ophthalmology Analytical Perspective by DelveInsight

In-depth Commercial Assessment: Gene Therapy in Ophthalmology Collaboration Analysis by Companies

The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

Gene Therapy in Ophthalmology Competitive Landscape

The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).

Gene Therapy in Ophthalmology Report Assessment

• Company Analysis
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Discover actionable insights into the Gene Therapy in Ophthalmology market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Gene Therapy in Ophthalmology Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Gene Therapy in Ophthalmology drugs?
• How many Gene Therapy in Ophthalmology drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gene Therapy in Ophthalmology?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gene Therapy in Ophthalmology therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Gene Therapy in Ophthalmology and their status?
• What are the key designations that have been granted to the emerging and approved drugs?

Gene Therapy in Ophthalmology Key Players

• Roche
• Neurotech Pharmaceuticals, Inc
• REGENXBIO Inc.
• PharmaMar
• Johnson & Johnson
• Frontera Therapeutics, Inc.
• Ray Therapeutics
• MeiraGTx
• Ocugen, Inc.
• 4D Molecular Therapeutics
• Atsena Therapeutics
• Nanoscope Therapeutics
• AAVantgarde Bio
• Complement Therapeutics
• PulseSight Therapeutics
• Opus Genetics
• SpliceBio
• Krystal Biotech
• GenEditBio
• Exegenesis
• IVIEW Therapeutics
• Kriya Therapeutics
• Chigenovo
• Coave Therapeutics
• Avirmax Biopharma

Gene Therapy in Ophthalmology Key Products

• Luxturna
• Encelto
• ABBV-RGX-314
• Tivanisiran
• JNJ-81201887
• FT-001
• RTX-015
• AAV-VEGFR2
• OCU400
• 4D-150
• ATSN-101
• MCO-010
• AAVB-081
• CTx001
• PST-611
• OPGx-LCA5
• SB-007
• KB803
• GEB-101
• EXG102-031
• GVB-2001
• KRIYA-825
• ZVS 101e
• CoTx 101
• ABI-201

Explore comprehensive insights into Gene Therapy in Ophthalmology epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.